Protalix BioTherapeutics (PLX) Competitors $2.28 -0.06 (-2.56%) Closing price 04/8/2025 04:00 PM EasternExtended Trading$2.28 0.00 (0.00%) As of 04/8/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock PLX vs. CMRX, EOLS, PRAX, AVDL, REPL, XNCR, NTLA, AVXL, GYRE, and RCKTShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Chimerix (CMRX), Evolus (EOLS), Praxis Precision Medicines (PRAX), Avadel Pharmaceuticals (AVDL), Replimune Group (REPL), Xencor (XNCR), Intellia Therapeutics (NTLA), Anavex Life Sciences (AVXL), Gyre Therapeutics (GYRE), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Chimerix Evolus Praxis Precision Medicines Avadel Pharmaceuticals Replimune Group Xencor Intellia Therapeutics Anavex Life Sciences Gyre Therapeutics Rocket Pharmaceuticals Protalix BioTherapeutics (NYSE:PLX) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking. Which has higher earnings and valuation, PLX or CMRX? Protalix BioTherapeutics has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$53.40M3.32$8.31M$0.0375.83Chimerix$212K3,772.07-$82.10M-$0.99-8.61 Is PLX or CMRX more profitable? Chimerix has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Chimerix's return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% Chimerix N/A -50.78%-44.94% Do insiders & institutionals believe in PLX or CMRX? 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 6.3% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 13.1% of Chimerix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer PLX or CMRX? Chimerix received 384 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 80.00% of users gave Protalix BioTherapeutics an outperform vote while only 63.16% of users gave Chimerix an outperform vote. CompanyUnderperformOutperformProtalix BioTherapeuticsOutperform Votes1280.00% Underperform Votes320.00% ChimerixOutperform Votes39663.16% Underperform Votes23136.84% Does the media refer more to PLX or CMRX? In the previous week, Chimerix had 4 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for Chimerix and 0 mentions for Protalix BioTherapeutics. Chimerix's average media sentiment score of 1.21 beat Protalix BioTherapeutics' score of 0.00 indicating that Chimerix is being referred to more favorably in the news media. Company Overall Sentiment Protalix BioTherapeutics Neutral Chimerix Positive Which has more volatility & risk, PLX or CMRX? Protalix BioTherapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Chimerix has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500. Do analysts recommend PLX or CMRX? Protalix BioTherapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 559.34%. Chimerix has a consensus target price of $8.53, suggesting a potential upside of 0.10%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protalix BioTherapeutics is more favorable than Chimerix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Chimerix 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryProtalix BioTherapeutics beats Chimerix on 10 of the 18 factors compared between the two stocks. Remove Ads Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$177.53M$2.70B$5.08B$17.21BDividend YieldN/A1.52%5.00%3.93%P/E Ratio-17.5028.4820.5128.81Price / Sales3.32402.18349.9723.96Price / Cash17.80168.6838.1517.54Price / Book4.843.286.044.00Net Income$8.31M-$72.06M$3.19B$1.02B7 Day Performance-10.43%-10.51%-7.80%-12.29%1 Month Performance-2.78%-25.27%-6.84%-13.87%1 Year Performance74.33%-37.25%0.13%-9.23% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeutics1.8394 of 5 stars$2.28-2.6%$15.00+557.9%+74.7%$177.92M$53.40M-17.54200Positive NewsHigh Trading VolumeCMRXChimerix3.1747 of 5 stars$8.51+0.1%$8.53+0.3%+751.0%$798.27M$212,000.00-9.0590Analyst ForecastNews CoveragePositive NewsEOLSEvolus3.7507 of 5 stars$12.03-0.2%$24.67+105.0%-29.6%$764.95M$266.27M-13.22170Gap DownPRAXPraxis Precision Medicines2.0134 of 5 stars$37.87-2.0%$123.33+225.7%-46.7%$763.57M$8.55M-3.68110Analyst ForecastNews CoverageGap UpHigh Trading VolumeAVDLAvadel Pharmaceuticals3.1799 of 5 stars$7.83-2.2%$19.88+153.8%-61.5%$756.61M$169.12M-9.9170News CoverageREPLReplimune Group3.3737 of 5 stars$9.75-6.2%$19.43+99.3%+0.3%$750.90MN/A-3.18210Gap UpXNCRXencor3.4561 of 5 stars$10.64-5.3%$34.38+223.1%-64.3%$749.72M$110.49M-3.33280News CoverageGap DownNTLAIntellia Therapeutics4.2607 of 5 stars$7.11-11.9%$37.56+428.2%-75.2%$736.01M$57.88M-1.31600Gap UpHigh Trading VolumeAVXLAnavex Life Sciences3.2215 of 5 stars$8.58-1.6%$44.00+412.8%+73.1%$729.85MN/A-15.6040Analyst ForecastNews CoveragePositive NewsGap DownGYREGyre Therapeutics0.0713 of 5 stars$7.72-15.3%N/A-57.1%$722.69M$105.76M154.4040Gap UpHigh Trading VolumeRCKTRocket Pharmaceuticals4.6021 of 5 stars$6.67-12.1%$43.00+544.7%-80.4%$711.22MN/A-2.43240News CoverageGap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Chimerix Alternatives Evolus Alternatives Praxis Precision Medicines Alternatives Avadel Pharmaceuticals Alternatives Replimune Group Alternatives Xencor Alternatives Intellia Therapeutics Alternatives Anavex Life Sciences Alternatives Gyre Therapeutics Alternatives Rocket Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PLX) was last updated on 4/9/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLX Stock Free PLX Stock Alerts